Sihuan Pharma Announces Second Anti-Virus Partnership with AMMS

Sihuan Pharma announced a second anti-viral collaboration with the Institute of Microbiology and Epidemiology of the Academy of Military Medical Sciences (AMMS). The newest project involves BR-01, an anti-adenovirus drug. The collaboration follows less than a week behind an agreement between Sihuan and AMMS for joint development of an AMMS-developed Ebola treatment. Sihuan expects BR-01 will prove effective as both a preventative and treatment for a broad spectrum of virus-caused illnesses. Financial terms of the collaboration were not made public. More details.... Stock Symbol: (HK 0460) Share this with colleagues: // //